+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Toxoplasma Gondii Recombinant Antigen Market by Product Type, Application, End User, Technology - Global Forecast to 2030

  • PDF Icon

    Report

  • 194 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6080705
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Understanding the Critical Role of Recombinant Antigens in Toxoplasma Gondii Diagnostics

Toxoplasma gondii remains a pervasive parasitic threat, especially among vulnerable populations such as pregnant women and immunocompromised individuals. In recent years, recombinant antigens have emerged as critical tools for enhancing the sensitivity and specificity of serological assays, enabling more accurate detection of both acute and chronic infections. This shift toward recombinant antigen-based diagnostics is driven by the demand for standardized, reproducible reagents that outperform traditional crude extracts.

Advancements in molecular biology techniques have accelerated the development of recombinant proteins that mimic the parasite’s immunodominant epitopes, reducing cross-reactivity and improving diagnostic confidence. As healthcare systems worldwide place greater emphasis on early identification and management of infectious diseases, reliable serodiagnostic platforms are increasingly essential for clinical laboratories, research institutes, and veterinary applications. The adoption of these novel antigens reflects a broader trend toward precision diagnostics, where tailored reagents provide clinicians and researchers with actionable data.

This report provides a comprehensive examination of the recombinant antigen market for Toxoplasma gondii, tracing the evolution of assay formats, exploring the influence of global trade policies, and highlighting the strategies of key stakeholders. By delving into segmentation by product type, application, end user, and technology, readers will gain a holistic understanding of current dynamics and future opportunities.

Emerging Technological and Clinical Shifts Reshaping the Toxoplasma Gondii Antigen Market

The landscape of Toxoplasma gondii recombinant antigen diagnostics is undergoing a transformative shift driven by technological breakthroughs and evolving clinical needs. Fluorescent multiplex immunoassays now enable simultaneous detection of multiple biomarkers, expediting workflows and delivering richer diagnostic data. At the same time, digital platforms equipped with advanced analytics and artificial intelligence are enhancing result interpretation and reducing the margin for human error.

Point-of-care testing has also gained traction, with lateral flow immunoassays now incorporating high-affinity recombinant proteins to achieve rapid, on-site detection without sacrificing accuracy. These portable formats support decentralized screening initiatives, particularly in resource-limited settings where laboratory infrastructure is sparse. Moreover, integration of microfluidic chips facilitates sample handling and reagent management, lowering the threshold for adoption by smaller clinics and field research teams.

Concurrently, there is a growing emphasis on harmonization of global regulatory standards to streamline approval pathways for novel diagnostic reagents. Collaborative efforts between industry consortia and regulatory bodies are fostering clearer guidelines for validation, quality control, and performance benchmarking. As a result, manufacturers are increasingly aligning product development strategies with international compliance requirements, accelerating time to market and widening the geographic reach of their offerings.

Evaluating the US Tariffs’ Cumulative Effects on Diagnostic Antigen Supply Chains in 2025

In 2025, the imposition of cumulative tariffs on imported diagnostic reagents has had a significant ripple effect across the Toxoplasma gondii antigen supply chain. Manufacturers dependent on overseas production of recombinant proteins have faced elevated input costs, compelling some to relocate portions of their operations to tariff-exempt jurisdictions. This geographic rebalancing has reduced exposure to trade volatility but introduced new logistical complexities as firms navigate diverse regulatory environments.

Higher duties on raw materials have also pressured reagent pricing, prompting distributors to reevaluate contract structures and negotiate longer-term agreements to lock in favorable rates. In certain markets, end users have experienced delayed procurement cycles due to budgetary constraints, spurring diagnostic developers to explore cost-saving measures. These include optimizing expression systems, enhancing protein yields, and leveraging single-use bioreactor technologies to streamline manufacturing.

Despite these headwinds, some companies have leveraged tariff-driven market shifts as an opportunity to differentiate through localized production and vertical integration. By investing in domestic fermentation facilities and establishing strategic partnerships with reagent suppliers, these players have regained margin stability and reinforced supply chain resilience. As 2025 unfolds, the enduring lesson is clear: adaptive sourcing strategies and agile manufacturing frameworks are essential for withstanding ongoing trade disruptions.

Deep Dive into Product, Application, End User and Technology Segmentation Trends

The recombinant antigen market for Toxoplasma gondii is characterized by distinct patterns emerging across diverse product types, from enzyme-linked immunosorbent assay kits to rapid test formats and Western blot systems. Within ELISA offerings, assays are further differentiated by their ability to perform IgG avidity testing, IgG detection, or IgM detection, each serving specific diagnostic milestones such as distinguishing recent from past infections. Rapid test kits, whether employing dipstick technology or lateral flow immunoassay, deliver point-of-care convenience that complements high-throughput laboratory platforms. Western blot products provide either qualitative visual confirmation or quantitative band intensity analysis, catering to confirmatory workflows in specialized diagnostic laboratories.

Applications for these recombinant antigens span clinical diagnosis, research use, and veterinary diagnostics. In clinical settings, precise serological profiling informs treatment decisions for immunocompromised patients, while research laboratories harness high-specificity reagents to explore host-parasite interactions at the molecular level. Veterinary practitioners employ these assays to monitor infection rates in livestock and companion animals, mitigating zoonotic transmission risks.

A broad ecosystem of end users, including academic institutes, diagnostic laboratories, hospitals, pharmaceutical firms, and dedicated research organizations, contributes to sustained demand for tailored assays. Underpinning these segments is a range of core technologies such as enzyme-linked immunosorbent assay, immunochromatographic assay, polymerase chain reaction, and Western blot. Each technological approach offers unique trade-offs in throughput, sensitivity, and operational complexity, influencing procurement priorities across institutional and regional contexts.

Regional Dynamics Driving Adoption of Toxoplasma Gondii Recombinant Antigen Solutions

Regional dynamics play a pivotal role in shaping the adoption trajectory of Toxoplasma gondii recombinant antigen diagnostics. In the Americas, robust research funding and a well-established healthcare infrastructure have driven rapid uptake of advanced ELISA and molecular platforms. Collaborations between academic centers and commercial entities continue to fuel innovation in assay development and validation.

Within Europe, Middle East and Africa, diverse regulatory landscapes present both opportunities and challenges. In Western Europe, stringent approval processes ensure high-quality standards yet require extended timelines for market entry. Conversely, emerging markets in the Middle East and Africa are accelerating adoption through public health initiatives aimed at controlling congenital toxoplasmosis, leveraging cost-effective rapid tests for mass screening programs.

The Asia-Pacific region has emerged as a significant growth engine, underpinned by rising healthcare expenditure and expanding diagnostics capabilities in countries such as China, India, and Japan. Investments in domestic manufacturing infrastructure have bolstered local production of recombinant antigens, reducing reliance on imports and enhancing supply chain agility. Cross-border collaborations and technology transfers further amplify the region’s role as a hub for next-generation diagnostic innovation.

Strategic Moves and Innovation Drivers among Leading Diagnostic Companies

Leading players in the recombinant antigen diagnostics arena have intensified their focus on portfolio expansion, strategic partnerships, and research collaborations to secure market share. Industry incumbents are investing heavily in recombinant protein engineering, exploring novel expression hosts and purification techniques to enhance antigen yield and purity. Concurrently, collaborations with academic laboratories have enabled the discovery of new immunodominant epitopes, laying the groundwork for next-generation assay formats.

Mergers and acquisitions remain an important lever for consolidating R&D capabilities and geographic reach, with several mid-sized companies aligning with global diagnostic conglomerates to accelerate product development. Strategic alliances with contract manufacturing organizations have also gained prominence, providing scalable production capacity while mitigating the capital expenditure associated with new facility builds. Furthermore, select firms are piloting digital platforms that integrate data management and advanced analytics, positioning themselves at the forefront of the convergence between diagnostics and data-driven healthcare.

This wave of strategic realignment underscores the competitive imperative to balance innovation with operational efficiency. Companies that can navigate regulatory complexities, scale manufacturing processes, and deliver high-performance reagents at competitive price points are poised to lead the next chapter of market growth.

Actionable Strategies for Industry Leaders to Capitalize on Market Opportunities

Industry leaders should prioritize investment in scalable expression systems that reduce production costs and enhance antigen consistency. Establishing regional manufacturing hubs will not only mitigate tariff-related risks but also shorten supply chains and improve responsiveness to local market demands. In parallel, companies must actively pursue partnerships with research institutions to accelerate the identification of novel antigen targets and validate their clinical performance.

Embracing digital transformation is equally critical. Integrating laboratory information management systems with diagnostic platforms can streamline data workflows, support real-time analytics, and facilitate compliance with evolving regulatory requirements. To maximize market penetration, firms should customize their product offerings to align with specific end-user needs, whether that entails simplified rapid tests for veterinary practitioners or multiplex ELISA panels for academic research.

Finally, engaging with regulatory bodies early in the development lifecycle will expedite approval processes and foster alignment on quality benchmarks. By adopting an adaptive go-to-market strategy that balances global scale with local relevance, industry leaders can capitalize on emerging opportunities and build a resilient foundation for sustained growth.

Rigorous Research Methodology Underpinning the Recombinant Antigen Market Analysis

This market analysis is grounded in a rigorous, multi-tiered research approach. Initial secondary research involved a comprehensive review of scientific literature, patent filings, regulatory submissions, and publicly available financial reports. Building on these insights, primary interviews were conducted with key opinion leaders, including diagnostic lab directors, academic researchers, veterinary specialists, and manufacturing executives, to validate findings and unearth nuanced perspectives.

Quantitative data was triangulated using multiple sources, encompassing trade databases, customs records, and proprietary sales data to ensure accuracy in assessing regional trade flows and competitive positioning. The segmentation framework was meticulously defined across product types, applications, end users, and underpinning technologies, with each category subjected to qualitative validation through expert consultations. Market dynamics, including tariff impacts and regulatory trends, were analyzed using scenario-based modeling to capture a spectrum of possible outcomes.

Quality control measures, such as cross-review by subject-matter experts and iterative feedback loops with stakeholders, were embedded throughout the research process. This methodology ensures that the report’s conclusions are both robust and actionable, providing stakeholders with a reliable foundation for strategic decision making.

Synthesis of Key Insights on the Recombinant Antigen Landscape

The recombinant antigen segment for Toxoplasma gondii diagnostics is poised at a critical juncture defined by technological innovation, regulatory harmonization, and strategic supply chain realignment. The convergence of advanced expression systems, digital analytics, and regional manufacturing initiatives has set the stage for more accessible and reliable serological assays. Meanwhile, the evolving trade landscape underscores the necessity of adaptive sourcing and localized production strategies.

Key market players are forging pathways through partnerships, mergers, and targeted R&D investment, reinforcing their competitive positioning while expanding the spectrum of available assay formats. End users across clinical, research, and veterinary domains stand to benefit from improved diagnostic confidence and operational efficiency. Ultimately, the insights presented herein illuminate the pathways by which stakeholders can navigate complexity, mitigate risk, and harness growth opportunities in the recombinant antigen market.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Elisa Kit
      • Igg Avidity Testing
      • Igg Detection
      • Igm Detection
    • Rapid Test Kit
      • Dipstick Test
      • Lateral Flow Immunoassay
    • Western Blot Kit
      • Qualitative Western Blot
      • Quantitative Western Blot
  • Application
    • Clinical Diagnosis
    • Research Use
    • Veterinary Diagnosis
  • End User
    • Academic Institutes
    • Diagnostic Laboratories
    • Hospitals
    • Pharmaceutical Companies
    • Research Institutes
  • Technology
    • Enzyme Linked Immunosorbent Assay
    • Immunochromatographic Assay
    • Polymerase Chain Reaction
    • Western Blot Assay
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Thermo Fisher Scientific, Inc.
  • F. Hoffmann-La Roche Ltd
  • Merck KGaA
  • Bio-Rad Laboratories, Inc.
  • QIAGEN N.V.
  • Bio-Techne Corporation
  • Abbott Laboratories
  • Abcam plc
  • GenScript Biotech Corporation
  • Meridian Bioscience, Inc.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Toxoplasma Gondii Recombinant Antigen Market, by Product Type
8.1. Introduction
8.2. Elisa Kit
8.2.1. Igg Avidity Testing
8.2.2. Igg Detection
8.2.3. Igm Detection
8.3. Rapid Test Kit
8.3.1. Dipstick Test
8.3.2. Lateral Flow Immunoassay
8.4. Western Blot Kit
8.4.1. Qualitative Western Blot
8.4.2. Quantitative Western Blot
9. Toxoplasma Gondii Recombinant Antigen Market, by Application
9.1. Introduction
9.2. Clinical Diagnosis
9.3. Research Use
9.4. Veterinary Diagnosis
10. Toxoplasma Gondii Recombinant Antigen Market, by End User
10.1. Introduction
10.2. Academic Institutes
10.3. Diagnostic Laboratories
10.4. Hospitals
10.5. Pharmaceutical Companies
10.6. Research Institutes
11. Toxoplasma Gondii Recombinant Antigen Market, by Technology
11.1. Introduction
11.2. Enzyme Linked Immunosorbent Assay
11.3. Immunochromatographic Assay
11.4. Polymerase Chain Reaction
11.5. Western Blot Assay
12. Americas Toxoplasma Gondii Recombinant Antigen Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Toxoplasma Gondii Recombinant Antigen Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Toxoplasma Gondii Recombinant Antigen Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Thermo Fisher Scientific, Inc.
15.3.2. F. Hoffmann-La Roche Ltd
15.3.3. Merck KGaA
15.3.4. Bio-Rad Laboratories, Inc.
15.3.5. QIAGEN N.V.
15.3.6. Bio-Techne Corporation
15.3.7. Abbott Laboratories
15.3.8. Abcam plc
15.3.9. GenScript Biotech Corporation
15.3.10. Meridian Bioscience, Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET MULTI-CURRENCY
FIGURE 2. TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET MULTI-LANGUAGE
FIGURE 3. TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY IGG AVIDITY TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY IGG DETECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY IGM DETECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DIPSTICK TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY QUALITATIVE WESTERN BLOT, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY QUANTITATIVE WESTERN BLOT, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY CLINICAL DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RESEARCH USE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY VETERINARY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC ASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT ASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 51. CANADA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 52. CANADA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 53. CANADA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 54. CANADA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 55. CANADA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 56. CANADA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. CANADA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 58. MEXICO TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 59. MEXICO TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 60. MEXICO TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 61. MEXICO TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 62. MEXICO TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 63. MEXICO TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. MEXICO TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 87. UNITED KINGDOM TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 88. UNITED KINGDOM TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 89. UNITED KINGDOM TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 90. UNITED KINGDOM TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 91. UNITED KINGDOM TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 92. UNITED KINGDOM TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. UNITED KINGDOM TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 94. GERMANY TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 95. GERMANY TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 96. GERMANY TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 97. GERMANY TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 98. GERMANY TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. GERMANY TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. GERMANY TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 101. FRANCE TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 102. FRANCE TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 103. FRANCE TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 104. FRANCE TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 105. FRANCE TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 106. FRANCE TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. FRANCE TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 108. RUSSIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 109. RUSSIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 110. RUSSIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 111. RUSSIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 112. RUSSIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 113. RUSSIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. RUSSIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 115. ITALY TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 116. ITALY TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 117. ITALY TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 118. ITALY TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 119. ITALY TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 120. ITALY TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. ITALY TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 122. SPAIN TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 123. SPAIN TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 124. SPAIN TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 125. SPAIN TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 126. SPAIN TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 127. SPAIN TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. SPAIN TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 129. UNITED ARAB EMIRATES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 130. UNITED ARAB EMIRATES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 131. UNITED ARAB EMIRATES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 132. UNITED ARAB EMIRATES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 133. UNITED ARAB EMIRATES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 134. UNITED ARAB EMIRATES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. UNITED ARAB EMIRATES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 136. SAUDI ARABIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 137. SAUDI ARABIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 138. SAUDI ARABIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 139. SAUDI ARABIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 140. SAUDI ARABIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 141. SAUDI ARABIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 142. SAUDI ARABIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 143. SOUTH AFRICA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 144. SOUTH AFRICA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 145. SOUTH AFRICA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 146. SOUTH AFRICA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 147. SOUTH AFRICA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 148. SOUTH AFRICA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. SOUTH AFRICA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 150. DENMARK TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 151. DENMARK TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 152. DENMARK TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 153. DENMARK TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 154. DENMARK TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 155. DENMARK TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. DENMARK TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 157. NETHERLANDS TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 158. NETHERLANDS TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 159. NETHERLANDS TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 160. NETHERLANDS TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 161. NETHERLANDS TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 162. NETHERLANDS TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. NETHERLANDS TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 164. QATAR TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 165. QATAR TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 166. QATAR TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 167. QATAR TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 168. QATAR TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 169. QATAR TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. QATAR TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 171. FINLAND TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 172. FINLAND TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 173. FINLAND TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 174. FINLAND TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 175. FINLAND TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 176. FINLAND TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. FINLAND TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 178. SWEDEN TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 179. SWEDEN TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 180. SWEDEN TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 181. SWEDEN TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 182. SWEDEN TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 183. SWEDEN TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 184. SWEDEN TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 185. NIGERIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 186. NIGERIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 187. NIGERIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 188. NIGERIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 189. NIGERIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 190. NIGERIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. NIGERIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 192. EGYPT TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 193. EGYPT TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 194. EGYPT TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 195. EGYPT TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 196. EGYPT TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 197. EGYPT TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. EGYPT TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 199. TURKEY TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 200. TURKEY TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 201. TURKEY TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 202. TURKEY TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 203. TURKEY TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 204. TURKEY TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 205. TURKEY TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 206. ISRAEL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 207. ISRAEL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 208. ISRAEL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 209. ISRAEL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 210. ISRAEL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 211. ISRAEL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 212. ISRAEL TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 213. NORWAY TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 214. NORWAY TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 215. NORWAY TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 216. NORWAY TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 217. NORWAY TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 218. NORWAY TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. NORWAY TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 220. POLAND TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 221. POLAND TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 222. POLAND TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 223. POLAND TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 224. POLAND TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 225. POLAND TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. POLAND TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 227. SWITZERLAND TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 228. SWITZERLAND TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 229. SWITZERLAND TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 230. SWITZERLAND TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 231. SWITZERLAND TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 232. SWITZERLAND TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. SWITZERLAND TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 239. ASIA-PACIFIC TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. ASIA-PACIFIC TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 241. ASIA-PACIFIC TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 242. CHINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 243. CHINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 244. CHINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 245. CHINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 246. CHINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 247. CHINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 248. CHINA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 249. INDIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 250. INDIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 251. INDIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 252. INDIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 253. INDIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 254. INDIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 255. INDIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 256. JAPAN TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 257. JAPAN TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 258. JAPAN TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 259. JAPAN TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 260. JAPAN TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 261. JAPAN TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 262. JAPAN TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 263. AUSTRALIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 264. AUSTRALIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 265. AUSTRALIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 266. AUSTRALIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 267. AUSTRALIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 268. AUSTRALIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. AUSTRALIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 270. SOUTH KOREA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 271. SOUTH KOREA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 272. SOUTH KOREA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 273. SOUTH KOREA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 274. SOUTH KOREA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 275. SOUTH KOREA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 276. SOUTH KOREA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 277. INDONESIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 278. INDONESIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 279. INDONESIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 280. INDONESIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 281. INDONESIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 282. INDONESIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 283. INDONESIA TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 284. THAILAND TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 285. THAILAND TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY ELISA KIT, 2018-2030 (USD MILLION)
TABLE 286. THAILAND TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY RAPID TEST KIT, 2018-2030 (USD MILLION)
TABLE 287. THAILAND TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY WESTERN BLOT KIT, 2018-2030 (USD MILLION)
TABLE 288. THAILAND TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 289. THAILAND TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 290. THAILAND TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 291. PHILIPPINES TOXOPLASMA GONDII RECOMBINANT ANTIGEN MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 292. PHILIPPINES TOXOPLASMA GONDII RECOMBIN

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Toxoplasma Gondii Recombinant Antigen market report include:
  • Thermo Fisher Scientific, Inc.
  • F. Hoffmann-La Roche Ltd
  • Merck KGaA
  • Bio-Rad Laboratories, Inc.
  • QIAGEN N.V.
  • Bio-Techne Corporation
  • Abbott Laboratories
  • Abcam plc
  • GenScript Biotech Corporation
  • Meridian Bioscience, Inc.